Role of Breast Cancer Inhibitors on Diabetes Mellitus- an in Silico Approach

Overview

Journal J Diabetes Metab Disord

Specialty Endocrinology

Date 2015 Mar 26

PMID 25806358

Citations 4

Authors

Shailima Dv Rampogu

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer and diabetes mellitus type-2 are two of the major diseases, which cause death to the women worldwide. Around 16% of the breast cancer patients also suffer from diabetes mellitus. It has been noted that the risk of occurrence of the breast cancer is more in patients suffering from diabetes mellitus.

Methods: Owing to this, the present article deals with an objective of using the breast cancer inhibitors for the diabetes drug target- 1ADS. Ten breast cancer inhibitors were drawn using Marvin Sketch. The docking was performed using Molegro software (Molegro Virtual Docker, MVD).

Results: The docking wizard generated 50 poses with the highest Mol Dock score -131.649.

Conclusion: This investigation successfully evaluated the effect of breast cancer inhibitors on diabetes mellitus, providing a new dimension in endocrine research.

Citing Articles

Molecular docking analysis of docetaxel analogues as duel lipocalin 2 inhibitors.

Ponnulakshmi R, Vidhya Rekha U, Padmini R, Perumal S, Saravanan R, Vishnupriya V Bioinformation. 2020; 16(6):438-443.

PMID: 32884206 PMC: 7452746. DOI: 10.6026/97320630016438.

Pharmacotherapeutics and Molecular Mechanism of Phytochemicals in Alleviating Hormone-Responsive Breast Cancer.

Rampogu S, Park C, Ravinder D, Son M, Baek A, Zeb A Oxid Med Cell Longev. 2019; 2019:5189490.

PMID: 31089409 PMC: 6476122. DOI: 10.1155/2019/5189490.

Exploring the Therapeutic Ability of Fenugreek against Type 2 Diabetes and Breast Cancer Employing Molecular Docking and Molecular Dynamics Simulations.

Rampogu S, Parameswaran S, Lemuel M, Lee K Evid Based Complement Alternat Med. 2018; 2018:1943203.

PMID: 30108647 PMC: 6077604. DOI: 10.1155/2018/1943203.

Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies.

Rampogu S, Son M, Park C, Kim H, Suh J, Lee K Biomed Res Int. 2018; 2017:2105610.

PMID: 29312992 PMC: 5664374. DOI: 10.1155/2017/2105610.

References

Anderson G, Chu E . Expanding priorities--confronting chronic disease in countries with low income. N Engl J Med. 2007; 356(3):209-11. DOI: 10.1056/NEJMp068182. View

Peairs K, Barone B, Snyder C, Yeh H, Stein K, Derr R . Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2010; 29(1):40-6. PMC: 3055858. DOI: 10.1200/JCO.2009.27.3011. View

Kador P, KINOSHITA J, Sharpless N . Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem. 1985; 28(7):841-9. DOI: 10.1021/jm00145a001. View

Su B, Tian R, Darby M, Brueggemeier R . Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification. J Med Chem. 2008; 51(5):1126-35. DOI: 10.1021/jm701107h. View

Muthenna P, Suryanarayana P, Gunda S, Petrash J, Reddy G . Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBS Lett. 2009; 583(22):3637-42. DOI: 10.1016/j.febslet.2009.10.042. View

Coughlin S, Calle E, Teras L, Petrelli J, Thun M . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159(12):1160-7. DOI: 10.1093/aje/kwh161. View

Ahmadieh H, Azar S . Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk. ISRN Endocrinol. 2013; 2013:181240. PMC: 3562674. DOI: 10.1155/2013/181240. View

Will J, Vinicor F, Calle E . Is diabetes mellitus associated with prostate cancer incidence and survival?. Epidemiology. 1999; 10(3):313-8. View

Mantzoros C, Tzonou A, Signorello L, Stampfer M, Trichopoulos D, Adami H . Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 1997; 76(9):1115-8. PMC: 2228109. DOI: 10.1038/bjc.1997.520. View

10.

Giovannucci E . Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res. 1999; 51 Suppl 3:34-41. DOI: 10.1159/000053160. View

11.

Liao S, Li J, Wei W, Wang L, Zhang Y, Li J . Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev. 2011; 12(4):1061-5. View

12.

Chan J, Stampfer M, Giovannucci E, Gann P, Ma J, Wilkinson P . Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998; 279(5350):563-6. DOI: 10.1126/science.279.5350.563. View

13.

Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C . Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999; 91(7):620-5. DOI: 10.1093/jnci/91.7.620. View

14.

Bohlke K, Cramer D, Trichopoulos D, Mantzoros C . Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology. 1998; 9(5):570-3. View

15.

Will J, Galuska D, Vinicor F, Calle E . Colorectal cancer: another complication of diabetes mellitus?. Am J Epidemiol. 1998; 147(9):816-25. DOI: 10.1093/oxfordjournals.aje.a009534. View

16.

Grimberg A, Cohen P . Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000; 183(1):1-9. PMC: 4144680. DOI: 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J. View

17.

Adami H, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D . Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991; 2(5):307-14. DOI: 10.1007/BF00051670. View

18.

Calle E, Murphy T, Rodriguez C, Thun M, Heath Jr C . Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998; 9(4):403-10. DOI: 10.1023/a:1008819701485. View

19.

Sowers J, Epstein M . Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995; 26(6 Pt 1):869-79. DOI: 10.1161/01.hyp.26.6.869. View

20.

Giovannucci E, Rimm E, Stampfer M, Colditz G, Willett W . Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control. 1998; 9(1):3-9. DOI: 10.1023/a:1008822917449. View